Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Removal of RNA Molecule Shown to Suppress Cancer Growth

By LabMedica International staff writers
Posted on 14 Jun 2011
New research demonstrated that the removal of a RNA molecule in mice could suppress carcinogenic tumor formation. More...


The study's findings were published in the journal Proceedings of the [US] National Academy of Sciences' early edition online in June 2011. Yong Li, PhD, associate professor of biochemistry and molecular biology at the University of Louisville (KY, USA) and his research team led by postdoctoral fellows Drs. Xiaodong Ma and Munish Kumar found that the removal of a noncoding RNA molecule known as microRNA 21 (miR-21) suppressed the formation of skin tumors in mice. This molecule was targeted for research because of its presence in human cancer formation, according to Dr. Li. "In virtually all types of cancer, miR-21 is found to be present at elevated levels," Dr. Li noted. "We believe it is essential to the growth of cancers."

Two groups of mice--18 with miR-21 removed and a control group of 23 with miR-21 intact--were evaluated after skin tumors known as papillomas were induced with a heavy dose of a carcinogen. The group without miR-21 had just 1.5 tumors per mouse after 30 weeks, as compared to 2.5 tumors per mouse in the control group. Moreover, one of the mice without miR-21 was tumor-free at the end of the study.

"Our work leads us to believe that miR-21 ablation increases the body's own tumor suppressing ability to hold back tumors," Dr. Li said. "The cancer research community is increasingly aware the importance of the surroundings around tumor cells. Our ongoing study of miR-21 involves looking at how this molecule contributes to tumor environment."

"We began our work in 2008 with the hypothesis that miR-21 plays a role in cardiovascular disease and diabetes," Dr. Li said. "However, our research and reports from other groups suggest it does not, although we are continuing our work in these areas. Funding basic research is important because you never know where science will take you. It is clear from our research that miR-21 is taking us a bit closer to understanding tumor formation."

Related Links:

University of Louisville





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.